Com­peti­tor man­u­fac­tur­ers could ben­e­fit from No­vo’s ac­qui­si­tion of Catal­ent, Siegfried CEO says

Phar­ma com­pa­nies could turn away from Catal­ent on the back of its $16.5 bil­lion ac­qui­si­tion by No­vo Hold­ings, which would al­low for fu­ture op­por­tu­ni­ties for oth­er CD­MOs, Siegfried CEO Wolf­gang Wien­and said dur­ing its earn­ings call with in­vestors this morn­ing.

“Our as­sump­tion is that No­vo Nordisk didn’t ac­quire the three sites in or­der to be­come a CD­MO but rather for [its] own ca­pac­i­ties for [its] own prod­ucts,” Wien­and not­ed. No­vo Nordisk will ab­sorb three man­u­fac­tur­ing sites from No­vo Hold­ings for $11 bil­lion to pro­duce its block­buster GLP-1 prod­ucts. Catal­ent has 47 oth­er sites.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER